A new Oliver Wyman study reveals costly findings about Part D beneficiaries enrolled in plans without preferred pharmacy networks.
Preferred pharmacy networks are a contributing factor in keeping premiums stable and affordable for Part D beneficiaries, according to a new study.
The study, from Oliver Wyman, commissioned by the Coalition for Affordable Prescription Drugs (CAPD), found that over the last four years, Part D beneficiaries enrolled in plans without preferred pharmacy networks pay twice as much in premiums (in the individual Prescription Drug Plan [PDP] market).
If Part D plans were unable to establish preferred pharmacy networks, federal spending on Medicare Part D would be $4.5 billion higher per year, according to the report. The report projects that federal spending on Medicare Part D would be roughly $45.8 billion higher between 2018 and 2026, if preferred pharmacy networks were not an option for Part D plans.
Additionally, plans that adopted a preferred pharmacy network in 2018 realized an average premium decrease of $14 per member per month, leading to an annual savings of $168 for those beneficiaries.
In November 2017, CMS published a proposed rule that included changes to the Any Willing Pharmacy provision for Medicare Part D.
Fitzpatrick
“These changes could potentially constrain Part D plan sponsors and their pharmacy benefit manager partners in tailoring preferred pharmacy networks,” says one of the study authors Randall Fitzpatrick, principal actuary at Oliver Wyman.
CAPD commissioned Oliver Wyman to look into the impact preferred pharmacy networks have on member premiums for the more than 21 million beneficiaries and federal spending.
The analysis estimated the impact of the elimination of the use of preferred pharmacy networks by PDPs, according to Fitzpatrick.
“In our work, we relied on publicly available data,” Fitzpatrick says. “Specifically, we used data from CMS that includes formularies for each PDP and enrollment and enrollee premiums by plan made available by CMS. Once we were able to identify the PDPs that employ preferred pharmacy networks, we used enrollment data to calculate the total beneficiaries enrolled in these plans.”
The next step in the researchers’ process was to determine the premium change assuming preferred pharmacy networks are eliminated. To accomplish this, they considered the average two-year premium increase for plans that changed from having a preferred pharmacy network to a standard pharmacy network and those plans that maintained a standard pharmacy network.
Other unique findings include:
A Conversation With Greg Baker, RPh, CEO of AffirmedRx
March 31st 2024Greg Baker, CEO of AffirmedRx, describes his early career, shares some of his critical opinions about the pharmacy benefit management (PBM) industry and how, in his view, his company is offering a better alternative.
Read More
David Calabrese of OptumRx Talks New Role, Market Insulin Prices and Other Topics 'On His Mind'
April 13th 2023In this month’s episode of the "What's On Your Mind podcast," Peter Wehrwein, managing editor of MHE connects with the now Chief Clinical Officer of OptumRx Integrated Pharmacies, David Calabrese. In this conversation, David touches on his transition in January as OptumRx’s former chief pharmacy officer and market president of health plans and PBMs to his new role as Chief Clinical Officer where he now focuses more on things such as specialty pharmacy to home delivery — with an overall goal of creating whole-patient care. Throughout the conversation, Calabrese also touched on the market’s hot topic of insulin prices and behavioral health services within the OptumRx community, among other topics.
Listen
Florida Gets the OK. But Will Drug Importation from Canada Actually Happen?
March 5th 2024Canadian health officials warn that maintaining a drug supply for Canadians is their priority. The staunch opposition of the U.S. pharmaceutical industry may also be an obstacle to imports from north of the border.
Read More
Briana Contreras, editor of Managed Healthcare Executive, spoke with Nancy Lurker, CEO and president of EyePoint Pharmaceuticals. Nancy shared a bit about EyePoint and how the organization’s innovative therapies are addressing patient needs through eye care, and most importantly, she addressed C-Suite positions like the CEO role. Nancy shared advice for those seeking to reach the CEO level, especially toward women in healthcare and other roles, and what it takes to run a biopharma company.
Listen
What Payers Need to Know As Retail Pharmacies Move Into Primary Care
September 6th 2023Healthcare beyond the doors of the doctor’s office has the potential to offer more care to more people. But payers need to think about how to ensure that care is consistent. Regardless of the setting, care decisions must be based on evidence-based content and supported with strong patient education.
Read More